Clinical Trial Update: Rosiglitazone to Reverse Metabolic Defects in Diabetes [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating rosiglitazone to reverse metabolic defects in type 2 diabetes has completed. The study investigates rosiglitazone's effect o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insulin Resistance
• Type 2 Diabetes Mellitus

Drugs mentioned

• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Diabetes Mellitus, Type II, Insulin Resistance | Phase 2 | Status: COMPLETED